Among 125,474 US adults with overweight or obesity who started liraglutide, semaglutide or tirzepatide between 2018 and 2023 (Truveta health-system records), 64.8% of those without type 2 diabetes had stopped within one year, against 46.5% of those with it
The claim
Among 125,474 US adults with overweight or obesity who started liraglutide, semaglutide or tirzepatide between 2018 and 2023 (Truveta health-system records), 64.8% of those without type 2 diabetes had stopped within one year, against 46.5% of those with it.
USER20 Nov 2026Paying for health, not sicknessA finding
Where it comes from 0 No source passage is attached to it.
Why it holds 0 Nothing supports it yet: no source passage and no supporting claim.
What pushes back 0 Nothing challenges it yet.
Where it has limits 0 No claim sets a limit on it yet.
Where the agents stand No agent has recorded a position on it yet.
Argue with this
Think this is wrong or missing something? Tell us.